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INTRODUCTION: EXPERIMENTS OF NATURE—
THE BEGINNINGS OF CELLULAR ENGINEERING
As first pointed out by Harvey [1] and reiterated by
McQuarrie [2], clinical investigators have at their disposal
powerful weapons with which to supplement tools available
from the basic sciences to contribute to the understanding
of the mechanisms of disease. Among patients, particularly
those with unusual diseases, may be found “experiments of
nature,” which permit a generation of new and useful
knowledge applicable far beyond the disease implications of
the patients studied.
It seems quite unimaginable today that when I began my
work in immunology in 1944, we knew very little about the
cells or molecules involved in immune defenses or about the
function of major organs now known to be crucial to
immunologic development and the function of the major
immune components, eg, thymus and spleen. I have had the
privilege to live and work at a time when I could contribute
to the development of much new knowledge in several dif-
ferent fields of immunology [3]. The development of our
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ABSTRACT
Primary immunodeficiency diseases often fully meet the definition of “experiments of nature.” Much of the expand-
ing understanding of the lymphoid systems and immunologic functions generated in recent years has been derived
from studying patients with primary, generally genetically determined immunodeficiency diseases, as well as other
relatively rare secondary immunodeficiency diseases. Increasing knowledge of immunologic defenses, their interact-
ing cellular and molecular components, the evolving details of sequential stages of cellular differentiation, and the
nature and control of the cellular and molecular interactions in immunity have now made it possible to define pre-
cisely many primary immunodeficiency diseases in full molecular genetic terms. With this wealth of scientific infor-
mation based on experimental and clinical research, incredible advances have also been made in using bone marrow
transplantation (BMT) often as a curative treatment for immunodeficiency, some 60 to 70 other diseases, leukemias,
lymphomas, other cancers, and a rapidly expanding constellation of metabolic diseases or enzyme deficiencies. Also,
progress in applying allogeneic BMT to prevent, treat, and cure complex autoimmune diseases, primary immunodefi-
ciency diseases and certain forms of cancers, is considered. Further, mixed BMT (syngeneic plus allogeneic) that
establishes a form of stable mixed chimerism has also been employed in animal experiments, which revealed that
BMT can be used to treat not only immunodeficiency diseases, but also systemic and organ-specific autoimmune dis-
eases, eg, diabetes and erythematous lupus-like diseases. Moreover, performing BMT in conjunction with organ allo-
grafts, eg, thymus or pancreatic transplants, has successfully prevented rejection of these allografts, sometimes without
recourse to long-term irradiation or toxic chemical immunosuppressive agents. A crucial role for stromal cells in cel-
lular engineering has now also been realized in animal models as a means of preventing graft rejection and promoting
full and persistent reconstitution or correction of genetically-based diseases. With all of these achievements, BMT
promises continued dramatic and impressive new approaches to clinical and scientific research and reveals an attrac-
tive strategy for the treatment and prevention of many currently intractable human diseases. If these achievements
can be extended to larger outbred animals and humans, BMT may set the stage for induction of improved immuno-
logic tolerance and for developing treatments for additional intractable human diseases in the 21st century.
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understanding is occurring so rapidly and with such impres-
sive precision that it is difﬁcult for modern-day immunolo-
gists to keep abreast of all aspects of the expanding under-
standing of immunologic function. But this explosion of
immunologic knowledge has taken place during my lifetime
as well as the lifetime of others who are still working pro-
ductively in this exciting ﬁeld.
Lessons learned from each of the forms of primary
immunodeficiencies have repeatedly shown that patients
with primary, generally genetically determined immunodeﬁ-
ciencies, are, indeed, most revealing “experiments of
nature.” Such patients, so vulnerable to infection, provide a
crucial testing ground for developing understanding of the
interrelationships between structure, differentiative influ-
ences, and function. The ability to correct by means of
organ, cellular, and molecular engineering the defects that
characterize patients with primary immunodeficiency dis-
eases and in this way to prevent the infectious and malignant
diseases that destroy such patients is a substantial witness to
the fact that the new knowledge of immunobiology has
pragmatic value. Thus, these “experiments of nature” led
my colleagues and me to analyze with increasing depth how
humans can exist usually free of infection while actually liv-
ing in a veritable sea of potential invaders—microorganisms
such as bacteria, fungi, parasites, and viruses with which
humans and mammals share their ecological niche.
PRIMARY IMMUNODEFICIENCIES
We know that the primary immunodeficiency diseases
usually result from innate genetic defects of the immune sys-
tem and its development. As a consequence, recurrent proto-
zoal, bacterial, fungal, and viral infections of varying severity;
autoimmunities; and malignant diseases ensue. Thus, patients
with immunodeﬁciency diseases have often become impor-
tant and sometimes crucial teachers of immunobiology: wit-
ness the bisection of the microbial universe, the lymphoid
system universe, and even the immunologic universes just
from the analysis of the antibody deﬁciency that feature the
X-linked form of agammaglobulinemia now known as Bru-
ton’s disease [4]. Indeed, when thoroughly studied, almost
every one of the primary immunodeficiencies have shed
signiﬁcant new light on the importance of immunologic func-
tions. In the past decade, even the genes and molecular bases
for several forms of human primary immunodeﬁciency dis-
eases have been identiﬁed. Some of these genes have already
been cloned and their function and expression characterized.
This better understanding of the molecular basis of primary
immunodeﬁciency disorders has led to improvement of avail-
able therapies—eg, bone marrow transplantation (BMT),
cord blood transplantation [5-7], stem cell transplantation
[8,9]—and to new treatment strategies, including gene ther-
apy [10,11], which have already been discovered and devel-
oped as effective treatments of immunodeﬁciency diseases
Herein we consider 5 of the primary immunodeﬁciency
diseases—X-linked agammaglobulinemia (XLA), X-linked
hyperimmunoglobulin (Ig)M syndrome (XHIM), X-linked
severe combined immunodeficiency disease (XLSCID),
adenosine-deaminase syndrome (ADA), and DiGeorge syn-
drome (DGS)—and reflect on the contributions each of
them has made to our modern concepts of immunology. 
The basic philosophy underlying the recognition of
the remarkable power of rare forms of disease as teachers
of modern biology and medicine was long ago recognized
and described in a letter written in 1657 by William Har-
vey [1] just 6 weeks before he died to a physician he
addressed as Jan Vlakfeld, “the distinguished and accom-
plished physician at Harlem.”
It is even so. Nature is nowhere accustomed more
openly to display her secret mysteries than in cases where
she shows traces of her workings apart from the beaten
path; nor is there any better way to advance the proper
practice of medicine than to give our minds to the discovery
of the usual law of nature, by the careful investigation of
cases of rarer forms of disease. For it has been found in
almost all things, that what they contain of useful or of
applicable, is hardly perceived unless we are deprived of them,
or they become deranged in some way. The case of the plas-
terer to which you refer is indeed a curious one, and might
supply a text for a lengthened commentary by way of illus-
tration. But it is in vain that you apply the spur to urge
me, at my present age, not mature merely but declining, to
gird myself for any new investigation. For I now consider
myself entitled to my discharge from duty. It will, however,
always be a pleasant sight for me to see distinguished men
like yourself engaged in this honorable arena. Farewell,
most learned sir, and whatever you do, still love.
Thus, according to Harvey, this beautiful prose summarizes
the influence that experiments of nature have exercised as
the great teachers of truths in medicine [1].
Bruton’s [4] discovery of agammaglobulinemia—and a
remarkable interplay between the clinic and laboratory—
opened the door to an impressive increase in our understand-
ing of the role played by lymph nodes, germinal centers, and
plasma cells in the bodily defense. The ﬁrst patients with this
disease were found to bisect the microbial universe, the
immunologic universe, and the lymphoid cellular universes in a
most dramatic way. These patients lacked plasma cells and the
precursors of plasma cells now called B lymphocytes, but they
had normal cell-mediated immunities [12-17]. This disease,
described for the ﬁrst time almost 58 years ago by Colonel
Ogden C. Bruton [4], is now a classic form of immunologic
deficiency. A disease of X-linked inheritance, XLA is now
known to be attributable to many different mutations of tyro-
sine kinase—Bruton’s tyrosine kinase (Btk) gene. The gene was
discovered in 1993 by 2 independent groups. Bruton tyrosine
kinase is a member of the Tec family of cytoplasmic protein
tyrosine kinases. These kinases are essential to the growth of B-
cell precursors and their development into mature B cells and
plasma cells, which is why there are no circulating B cells in
patients with XLA [18,19]. More than 300 different mutations
in the Btk gene have been identiﬁed, but there has not been
any correlation between the type of mutation and the pheno-
type of the disease. Children with XLA or deﬁcient Ig produc-
tion are protected against infection during the ﬁrst few months
of life by maternally transmitted IgG antibodies. Thereafter,
they are susceptible to recurrent bacterial infections with encap-
sulated organisms such as Haemophilus inﬂuenzae, Streptococcus
pneumoniae and, less frequently, Staphylcoccus aureus, which are
often manifested during the second half of the ﬁrst year of life
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in these patients. The most characteristic ﬁnding in infants
with XLA is the arrest of B lymphocyte development in the
peripheral blood and lymphoid tissues [20,21]. Bruton reported
the case of an 8-year-old boy who had suffered since an early
age from recurrent bacterial infections. It has been noticed by
several investigators, including ourselves, that the boy
described by Bruton may not have had what we now recognize
as XLA [22-24]. However, certain patients with XLA, as con-
ﬁrmed by mutation analysis, have demonstrated a relatively
mild disease phenotype similar to Bruton’s case [4,25-27]. In a
joint study, Bruton et al. [28] reported additional patients in
whom the diagnosis of XLA seems indisputable. More impor-
tantly, however, is that Bruton’s original report inspired a great
number of investigators, including ourselves, to look for
patients with antibody or cellular immunodeﬁciencies. This
search turned up numerous patients who were identiﬁed not
only with XLA, but with other forms of primary immunodeﬁ-
ciency as well [3,29].
X-Linked Hyper IgM Syndrome
XHIM is a rare inherited immune deﬁciency disease. This
disease was ﬁrst described in 1961 and appeared to be an X-
linked syndrome that resembled XLA clinically. XHIM
patients, however, were found to have normal or elevated
serum concentrations of IgM but no IgA and little or no IgG
or IgE [30,31]. Male patients with XHIM syndrome have a
clinical history of pyogenic infections that resembles that
encountered in male patients with XLA [32]. They also have a
high frequency of autoimmune disorders and cancers [33]. In
addition, these patients, for unknown reasons, are susceptible
to infections other than those due to high-grade encapsulated
bacteria that plague the patients with XLA. XHIM patients
may particularly experience infections due to Pneumocystis
carinii. Patients with XHIM are also prone to exhibit apparent
autoimmune diseases, eg, hemolytic anemia, thrombocytopenic
purpura, and recurrent, often severe, persistent, and prolonged
neutropenias. These disease entities are often observed with T-
cell immunodeficiencies but are not often encountered in
patients with XLA or other forms of agammaglobulinemia and
defective antibody production. Despite lymphoid hyperplasia,
which distinguishes XHIM from XLA, lymph nodes in XHIM
patients are characteristically devoid of well-developed germi-
nal centers [33,34]; these patients cannot switch normally from
production of IgM antibodies to production of IgG, IgA, or
IgE antibodies because they lack the molecular essence of the
switch mechanism, CD40 ligand. This disease has now been
found to be attributable to mutations in the CD40 ligand
(CD40L) gene [35-39]. The ligand for CD40 is a membrane
protein present on activated T cells that has the capacity to
induce a characteristic B-cell proliferation and differentiation
to plasma cells. Several mutations of the CD40L gene were
reported to be responsible for defective class switching of B
cells in X-linked immunodeficiency with hyper IgM [40],
resulting in failure to mount normal secondary antibody
responses to T cell– dependent antigens, accounting for the
increased susceptibility to infections [33]. Further work is
required to explain the high frequency of autoimmune disease
and prolonged episodes of neutropenia and susceptibility to
opportunistic infections, including those due to Pneumocystis
carnii pneumonia and lymphoproliferative complications that occur
in patients with XHIM. If these patients live long enough, they
are likely to develop lymphoid malignancies that appear to
involve especially cells of the B-cell series. These patients have
recently been fully reconstructed immunologically by BMT
from a major histocompatibility complex (MHC)-matched sib-
ling donor, and their genetic abnormality has also been fully
corrected by BMT in recent experiments [41].
X-Linked Severe Combined Immunodeficiency
Disease and Adenosine Deaminase Deficiency
Hyper IgM syndrome can occur either in an X-linked
form or in several autosomal recessive genetic forms. Unlike
the X-linked form, the autosomal recessive form is not
attributable to an abnormality of the CD40 ligand switch
mechanism. Patients with XLSCID have a collection of
abnormalities of the gene for interleukin (IL)-2Rγ, which
may also act as a receptor for IL-2, IL-4, IL-7, IL-9, IL-15,
and IL-2Rγc. XLSCID causes susceptibility to infection
attributable to deficiencies of both cellular and humoral
immunity early in life, often in the ﬁrst days or weeks of life.
Among different variants, SCID has also been found to be
caused by a deﬁciency in the ADA enzyme in which lympho-
toxic metabolites prevent normal development of T cells as
well as B cells and plasma cell accumulation. The in-depth
understanding of the biochemical and molecular basis of this
disease has allowed the development of a number of experi-
mental therapies for ADA-SCID. Patients with XSCID have
decreased numbers of T cells but are able to produce B cells.
They fail to exhibit normal proliferative responses to phy-
tomitogens and also exhibit hypogammaglobulinemia and
failure of antibody production, although B cells are often
present but probably in a diminished number [42]. Before
1968, patients with XSCID always died of infections within
the ﬁrst and second years of life. However, the achievement
of immune reconstitution following the ﬁrst successful allo-
geneic BMT (allo BMT) [43-46] marked the beginning of an
era that has unlocked the door to future successes with BMT
as a treatment for immunodeﬁciencies and paved the way to
successful gene therapy, often thought of as the ultimate
treatment for inherited immunodeﬁciency diseases [11,47].
SCID of the X-linked type and that associated with ADA
deficiency were thought to offer ideal targets for the first
clinical application of gene therapy [48] because SCID is a
lethal condition that is, in many cases, curable by alloBMT.
Over 2 decades, identiﬁcation of ADA deﬁciency, which
severely impairs immunity, has provided the molecular basis
for approximately 40% of autosomal recessive cases of
SCID. In this inherited disorder, early descriptions of clinical
and pathologic manifestations in ADA deﬁciency in SCID
patients were based on studies of children diagnosed as
having classic SCID with marked developmental delay and
failure to thrive [49]. Because of the original means of identi-
fying patients to be tested for ADA deficiency, the initial
cases seemed clinically and immunologically indistinguish-
able from patients with other forms of classic SCID. How-
ever, they exhibited an autosomal recessive inheritance.
These ADA-deﬁcient patients had a disease of neonatal onset
usually characterized by lymphopenia, absence of both cellu-
lar and humoral immune function, and deﬁciency of both T
and B lymphocytes, which led to infections with bacterial,
viral, or opportunistic pathogens, eg, Pneumocystis carinii [49].
ADA is the most extensively studied of all the congenital
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immunodeﬁciency diseases because it was the ﬁrst immunod-
eﬁciency disease in which the molecular defect had been fully
identiﬁed [50] and was the ﬁrst disease in which the responsi-
ble gene had been cloned [51-54]. ADA deﬁciency was thus
described as the underlying problem treated in the first
apparently only partially successful gene therapy [47] because
of a number of characteristics that have made it a particularly
attractive candidate for gene therapy. The involved gene was
isolated independently in 1983 by 3 groups, providing inves-
tigators almost a decade to gain experience by investigating
the gene, its function, and its regulation [51-54]. A landmark
finding by Fischer and coworkers in Paris [11] recently
described a more dramatic and complete cure of immunode-
ﬁciency using a technique similar to that thought to be effec-
tive in ADA-deﬁcient patients by Blaese and Culver [47] and
Anderson [48]. The French team’s results demonstrate
clearly that in patients with XLSCID, a selective advantage
was conferred on both T- and natural killer (NK) lympho-
cyte progenitors, which enabled full-blown development of
mature and functioning T and NK lymphocytes [55] as well
as reconstitution of B lymphocytes, immunoglobulin, and
antibody synthesis. Thus, this has become an era of gene
therapy with exciting developing technology that will allow
for treatment of various congenital and acquired genetic dis-
orders as well as infectious diseases. Successful clinical trials
in the next century should make gene therapy an efﬁcacious,
accepted approach, revolutionizing the treatment of numer-
ous diseases—including immunodeﬁciencies, certain cancers,
and other genetic diseases—and translating scientiﬁc knowl-
edge into clinical reality [10,56,57].
Correction of DiGeorge Syndrome by Thymus
Transplantation
DGS was ﬁrst considered a rare disorder attributable to
failure to develop the thymus and other derivatives of the
third and fourth pharyngeal pouches, which explains the asso-
ciation of hypoparathyroidism, malformations of the aortic
arch, and facial abnormalities. These patients were found to
have hypoplasia of both the thymus and the parathyroid
glands. This disease was recognized and first described by
Angelo DiGeorge, a Philadelphia endocrinologist [58]. This
“experiment of nature” became a major subject of investiga-
tion for geneticists and immunologists. No sooner had
Cooper et al. [59-62] and Warner et al. [63] presented their
ﬁndings differentiating the separate origins of 2 distinct lym-
phoid systems [64], than DiGeorge [65] described the com-
plex set of developmental anomalies that provide the human
counterpart of the Minnesota animal experiments that in
human, as in the chicken [59] and the rabbit [66], separate
central lymphoid organs control the maturation of humoral
and cellular immune functions. DiGeorge recognized that
survival of these athymic patients was limited by overwhelm-
ing susceptibility to infection due to failure to develop thy-
mus-dependent immunocompetence, which is characterized
by failure to develop a T cell–dependent immunity. There-
fore, it was natural to consider the possibility of correcting
this clinical immunologic anomaly by transplantation of thy-
mus, as had been so successful in correcting the immunodeﬁ-
ciency of neonatally thymectomized mice [67,68]. In 1995,
Markert et al. [69] successfully showed that using discarded
postnatal thymic tissue grafts that were partially MHC-
matched with the recipient permitted maturation of normally
functioning T cells identiﬁed in peripheral blood. Antigen-
speciﬁc T-cell responses were also developed and B-cell func-
tion normalized in the DiGeorge patients. More recently,
Markert et al. [70] have corrected 2 patients with the most
complete form of DiGeorge thymic aplasia by transplantation
of MHC-matched thymus grafts from unrelated donors when
a portion of MHC-matched thymus was obtained at surgery
for congenital heart disease. Typically, DGS patients have
severely impaired production and function of T cells,
decreased lymphocytes in the deep cortical areas of the lymph
nodes, and increased susceptibility to viral infections. They
also exhibit an increased risk of autoimmune diseases and
virus diseases such as parainﬂuenza, adenovirus, and rotavirus,
which have caused morbidity in DGS patients [71,72]. The
initial apparent success of thymus transplantation from sev-
eral analyses proved spurious, but MHC-matched allogeneic
thymus transplantations did correct the deﬁciency in produc-
ing T cells in DGS patients. Recent studies also showed that
the immune reconstitution was due to restitution of ability to
produce new T cells and to generate T cell receptor recombi-
nation excision circles (TRECs) within the thymus [73].
TRECs are the episomal circular DNA excision products of
the T cell–receptor gene that are not replicated with cell divi-
sion and therefore thought to be a marker for cells that have
recently emigrated from the thymus. In 1 patient, there was
also evidence of thymus function and CD45RA + CD62L +
T cells more than 5 years after transplantation [70]. Thus,
“experiments of nature” in the clinic provided crucial ques-
tions of fundamental nature to be taken to the laboratory and
a testing ground for the usefulness of the developing under-
standing of lymphoid development. Cleveland et al. [74] and
soon thereafter August et al. [75] achieved apparent impres-
sive correction of immunologic function in children with
DGS by transplantation of an embryonic thymus.
FIRST SUCCESSFUL CURE OF HUMAN DISEASE BY BMT
The cellular basis of immunodeﬁciencies thus seemed to
have been greatly clariﬁed. Strategies to correct by “cellular
engineering” some of those primary immunodeﬁciencies of
humans occupied much of our scientiﬁc and clinical attention.
These new insights were soon followed by attempts to correct
clinical immunodeﬁciency using transplantation of competent
immunologic tissue. Based on the anomalies in XLA, DGS
and SCID, we reasoned that SCID should be correctable by
transplantation using either bone marrow or fetal liver as a
source of normal lymphoid progenitor cells. As a ﬁrst effort
along with Richard Hong, we performed a fetal liver trans-
plantation in a young child with autosomal recessive SCID
[76]. Soon we had our first potential BMT recipient. Dr.
Jerome L’Heureux, a pediatrician in Meridian, Connecticut,
had heard me discuss BMT and contacted me regarding a
child he was treating for SCID. This 4-month-old boy came
from a family in which 11 male children had died from
XLSCID. The infant already had had 3 or 4 bouts of pneumo-
nia and most certainly would have succumbed to lethal infec-
tion soon thereafter. We were relieved to ﬁnd that the little
boy matched relatively well at the MHC with one of his sis-
ters. So, in 1968 with our clinical research team, we cured a
hereditary and lethal disease, XLSCID, for the very ﬁrst time
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by alloBMT [43-46]. However, the child was not perfectly
matched with his sister, who was the best donor available but
mismatched at the AMHC locus [77] due to a crossover event
in the family. Consequently, he developed a severe graft-ver-
sus-host reaction that led in turn, to severe aplastic anemia.
Instead of attempting to eliminate the bone marrow graft (as
others suggested) that all recognized to have cured the mani-
festations of primary immunodeficiency, we took steps to
apply BMT for the very ﬁrst time to cure also severe aplastic
anemia [45,46,78,79] using a second marrow transplant. This
resulted in full immunologic, lymphoid, and hematopoietic
reconstitution. The boy’s red blood cell type switched from his
genetic A type to his sister’s group O. Indeed, all of his
hematopoietic cells that could be made to divide exhibited a
female karyotype. He became completely well and has
remained healthy and immunologically vigorous for more
than 33 years. An aspect which seemed perplexing at ﬁrst is
most interesting. After the initial transplant, this boy devel-
oped a sensitivity to mumps antigen, which has persisted to
the present time, suggesting that, perhaps, a peripheral T-cell
immunity system derived from the sister was included in his
immunologic makeup. Twice he was intimately exposed to
chicken pox but failed to develop the disease because his sister,
whose marrow cells corrected his immunodeficiency, had
already become immune to this disease. These findings,
though inconclusive, suggest that the ﬁrst case of successful
transplantation of peripheral immunocompetent cells and
reconstitution with stem cells had been achieved in this child.
These 2 BMTs were the ﬁrst successful alloBMTs in the world
and they cured 2 different otherwise fatal diseases. The ﬁrst
cured SCID, and the second sustained that cure and also cured
severe aplastic anemia in the same child [43-46,78,79].
EARLIER EXPERIMENTS WITH BMT USING MOUSE
MODELS
Allogeneic BMT After Lethal Total Body Irradiation
Has Been Used to Cure Organ-Specific and Systemic
Autoimmune Diseases
Our understanding of the immunologic processes has
recently been increased markedly by analysis in experimen-
tal animal models of immunologic abnormalities and by
continued study of human diseases. With Ikehara [80] we
had shown that autoimmune diseases appear to be attribut-
able to genetic abnormalities of stem cells and had found
that allogeneic but not syngeneic BMT can correct and cure
many autoimmunities using marrow from MHC-identical
donors. This might be a preferable approach to treatments
of autoimmunities as well as immunodeficiencies. In
humans, however, alloBMT across MHC barriers often
fails, frequently due to graft-versus-host reaction arising
from contamination of blood marrow with T cells and rejec-
tions based on graft-versus-host rejection; or to hemato-
poietic (BMT) competition [80]. Onoé et al. [81] showed that
in autoimmune-prone mice, no such problems arise with the
alloBMT when the bone marrow used comprises bone mar-
row cells that have been completely depleted of T cells and
if myeloablation and immunosuppression of the recipients
have been adequate. The rationale for using BMT for pre-
vention and treatment of autoimmune diseases is that we
had found that the autoimmunities apparently reside in the
hematopoietic stem cells (HSCs). Fully alloBMT can often
cure these systemic as well as organ-specific autoimmune
diseases whereas syngeneic BMT regularly failed to cure
these genetically-based autoimmune diseases [80,82].
Complex BMT—Prevention and Treatment of 
Organ-Specific Autoimmune Disease by BMT 
Plus Organ Allografts
Diabetes mellitus is a heterogeneous disorder, and its
pathogenesis remains an enigma. Type I diabetes is insulin-
dependent and of juvenile onset. Nonobese diabetic (NOD)
mice provide a splendid model of type I diabetes mellitus. In
our earlier experiments with Ikehara and his group, we
demonstrated that alloBMT can be effectively used to treat
systemic autoimmune diseases in (NZB × NZW)F1–speciﬁc
pathogen-free mice without inducing graft-versus-host reac-
tion, provided that bone marrow cells of young BALB/c nu
nu donor mice or T cell–depleted marrow (TCDM) cells
have been used [82].
These observations prompted us to examine whether or
not insulitis as an organ-speciﬁc autoimmune phenomenon
can also be treated by allogeneic or syngeneic BMT. In the
ﬁrst study [83], we showed that the lymphocytes inﬁltrating
into the islets are T cells and that alloBMT can, after lethal
total body irradiation (TBI), be used to treat this insulitis
and prevent overt diabetes. The newly developed T cells in
the allogeneic bone marrow recipients were found to be tol-
erant to cells with both donor- and host-type MHC deter-
minants, suggesting that BMT may ultimately be developed
as a component of treatment of type I diabetes in humans.
BMT for Type I Diabetes Mellitus
With Ikehara, we performed a combined transplantation
of fetal or newborn pancreas plus allogeneic bone marrow
because we know that organ allografts are accepted if the
organ and the bone marrow are from the same MHC-
matched donor and transplanted at the same time [84]. NOD
mice that had already developed overt diabetes accompanied
by destruction of all islet β cells were lethally irradiated and
then reconstituted with allogeneic BALB/c bone marrow
cells. The pancreatic tissues from fetal or newborn BALB/c
mice were then engrafted under the renal capsules of NOD
mice that underwent BMT. Three months after transplanta-
tion, the mice exhibited normal correction to glucose levels
and a correction to normal responses in the glucose tolerance
test. As neither insulitis nor rejection occurred, we had suc-
ceeded in treating type I diabetes by the combined transplan-
tation of pancreas and bone marrow, which worked very well.
Hyperglycemia was reversed and eliminated, deﬁcient glucose
tolerance curves were corrected, and circulating insulin levels
increased from low to normal ranges [85].
Complex BMT—Successful BMT Plus Bone Grafts
Were Used to Prepare Mixed Chimeras in
Autoimmune Combinations That Otherwise 
Resisted Stable Chimera Formation
The HSCs of MRL/lpr mice are abnormally radioresis-
tant to TBI. Even after successful BMT, these mice improve
initially but regularly suffer progressive relapse of their lym-
phoproliferative syndrome and redevelop autoimmune dis-
ease after conventional BMT [86]. We have recently found
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that there is an MHC restriction between HSCs and stromal
cells as well as between lymphoid cells [88]. To prevent recur-
rence of autoimmune diseases in MRL/lpr mice, Ikehara’s
group carried out both BMTs and bone grafts to replace not
only hematopoietic cells, but also stromal cells with donor
stromal cells. When bones have engrafted along with BMT,
donor-derived stromal cells present in the engrafted bones
migrate into the recipient bone marrow and the latter are
then replaced with both donor-derived stromal cells and
donor-type hematopoietic cells. Based on these findings,
attempts were made to prevent the recurrence of autoim-
mune diseases, such as systemic lupus erythematosus and
rheumatoid arthritis, in MRL/lpr mice by the transplantation
of both bone marrow cells and bone grafts. Thus MRL/lpr
mice had TBI (8.5 Gy) and then were reconstituted with
C57BL/6 bone marrow cells plus bone grafts. These mice
were given a new long-term lease on a healthy life and were
also prevented from experiencing recurrence of the autoim-
mune or lymphoproliferative disease [87]. Using another
chimeric-resistant combination (DBA/2 → C57BL/6), Hisha
et al. [88] conﬁrmed that chimeric resistance can be overcome
by BMT plus bone grafts when co-grafting DBA/2 donor
bones from which the hematopoietic cells had been removed
but in which stromal cells remained. In another study, Naka-
gawa et al. [89] showed that allogeneic bone marrow cells plus
bone transplantation enable the complete prevention and cor-
rection of joint disease in male NZB/Kn mice, which sponta-
neously develop severe inﬂammatory polyarthritis at the age
of 4 months, followed by gait disturbances and progressive
swelling and ankylosis of the joints of the paws. Our ﬁndings
indicate that BMT alone did not cure this experimental
arthritis. But when BMT plus bone transplants were given to
the NZB/Kn mice, their severe rheumatoid arthritis was also
cured [87-89].
Complex BMT and Other Transplantations to Cure
Autoimmune Diseases—BMT With Fetal Thymus
Transplantation
Old congenic MRL/+ mice develop both pancreatitis
and sialoadenitis. These symptoms are similar to those in
human patients with Sjögrens syndrome. It is well known
[90] that in humans, the success rate of BMT in patients
older than 45 years is low. Recently, it has been shown [91]
that the low success rate of curing this experimental type of
Sjögrens disease by BMT was due to the aging of the thy-
mus and that either bone marrow or fetal HSCs plus frag-
ments of adult or fetal bone plus embryonal thymus grafts
can be successfully employed to treat the late-onset Sjö-
grens-like autoimmune diseases in MRL/+ female mice. A
Sjögrens-like syndrome that occurs in these aging old
MRL/+ mice could not be cured by lethal TBI plus conven-
tional BMT alone. However, if BMT plus a fetal thymus
transplantation plus bone transplantations were all used, the
Sjögren’s syndrome appeared to be completely cured. This
combination of BMT plus bone plus fetal thymus transplan-
tation represents a potentially important new strategy for
cellular engineering that can possibly cure the experimental
form of Sjögren’s syndrome and, thus, possibly cure a com-
plex autoimmune disease that could not be cured by BMT
alone. This approach needs to be considered in the present
context [91].
Haploidentical BMT for Occlusive Coronary Vascular
Disease
In some ways, the hemolytic anemias are the best stud-
ied autoimmune diseases of humans. In some instances, the
actual antibodies are known precisely. In other instances,
evidence of antibody reacting with the red blood cells and
participation of complement have been demonstrated. Mice
of the New Zealand Black (NZB) strain regularly develop
autoimmune hemolytic anemia plus hyalinizying renal
lesions similar to the lesions observed in lupus erythemato-
sus. When NZB mice are mated to normal New Zealand
White (NZW) mice, the F1 offspring (NZB × NZW)F1
combination or B/W mice develop elevated titers of
antinuclear autoantibodies, anti–double stranded DNA
(anti-dsDNA), and anti-cardiolipin autoantibodies. These
mice die early in life from progressive glomerulonephritis.
They also may exhibit accelerated coronary artery disease
[92-94]. Both the advanced and progressive renal disease
and the coronary artery disease were corrected and cured by
successful BMT. In another study [95], we used reciprocal
haploidentical BMT to determine whether the occlusive
coronary vascular disease (CVD) of male (NZW × BXSB)F1
(W/B)F1 mice is treatable or transferable as a component of
the systemic autoimmunity arising from abnormalities in
hematopoietic marrow. TCDM of male W/BF1 mice was
transplanted into autoimmune-resistant B6C3F1 mice.
CVD developed only in otherwise healthy mice with sys-
temic autoimmunity causing the coronary vascular lesions
and the glomerulonephritis. These results indicate that
murine lupus-associated CVD may be a reflection of sys-
temic autoimmunity that is transferable by TCD BMT to
nonautoimmune recipients. Further, these findings show
that similarities in the pathogenesis of human and murine
lupus-associated CVD exist [95].
BMT for Prevention of Crescentic
Glomerulonephritis Disease
Rapidly progressive crescentic glomerulonephritis fre-
quently occurs concomitantly with certain forms of vasculi-
tis, including Wegener’s granulomatosis and small vessel
polyarteritis nodosa [96-98]. Kinjoh et al. [99] working in
our laboratory bred a new inbred strain of mice by breeding
that used selection for crescentic glomerulonephritis to
express a highly lethal form of crescentic glomerulonephritis
and also small vessel polyarteritis nodosa. These mice, when
treated by BMT from BALB/c donors, showed inhibition of
and even reversal of the polyarteritis nodes and a crescentic
glomerulonephritis after transplantation of bone marrow
from the BALB/c donors. The mice of this new SCG/Kj
strain also showed autoantibodies similar to antineutrophilic
cytoplasmic autoantibody that were suppressed after BMT
from healthy nonautoimmune donors [100].
Mixed BMT for Induction of Immunologic Tolerance
Ildstad et al. [101] found that chimeras that received
transplants of mixed TCDM from both allogeneic and syn-
geneic donors can fully reconstitute hematopoietic and
immunologic function after supralethal TBI; these mixed
bone marrow chimeras do not express the immunologic
deﬁcits observed after TBI plus BMT with fully allogeneic
bone marrow. Reﬂection on these ﬁndings caused El-Badri
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et al. [102] to extend Ildstad’s research by showing, frequent
survival with stable mixed chimerism and normally vigorous,
functioning immune systems in C57BL/6 mice that received
transplants of TCDM from both BALB/c allogeneic donors
and C57BL/6 syngeneic donors that differed from each
other across the entire MHC barriers. These stable mixed
chimeras did not have the immunodeﬁciencies that are regu-
larly observed in fully allogeneic chimeras [102].
Mixed BMT as a Well-Tolerated Cure for
Autoimmunities
Wang et al. [103] in my laboratory then tested the possi-
bility of developing BMT further to prevent autoimmune
diseases and reconstruct the full immune functions of irradi-
ated mice at the same time by transplanting mixed TCDM
from both allogeneic normal healthy autoimmune-resistant
donor mice and syngeneic autoimmune-prone donor mice
into lethally irradiated autoimmune-prone BXSB recipients.
Mice of this BXSB strain develop a spontaneous and highly
lethal lupus-like illness, and the disease is worse in males
than in females [104]. Acceleration of disease phenotype in
males is due to a Y chromosome gene termed the Y chromo-
some autoimmune accelerator (Yaa). The function of these
gene is not known except that when expressed in a suscepti-
ble strain it is able to cause disease [105]. Subsequently, in
1999, Wang et al. [106] attempted to prevent autoimmune
diseases and, at the same time, to reconstruct full immunity
functions of irradiated autoimmune mice by transplanting
mixed TCDM from both the allogeneic autoimmune-
resistant donor and the syngeneic autoimmune-prone donor
marrow into lethally irradiated BXSB recipients. This
approach of creating stable mixed chimerism proved to be a
highly successful treatment of numerous manifestations of
autoimmune disease. The concomitant regularly fatal
chronic renal disease was corrected and could be both pre-
vented and cured in the BXSB mice [103,106].
Osteoblasts as Facilitators of Allogeneic Stem Cell
Engraftment
Because interaction of stem cells with the bone marrow
stromal microenvironment is required for development, matu-
ration, and differentiation of HSCs and because bone trans-
plants have been found to facilitate BMT in some combina-
tions, El-Badri et al. [107] tested bone progenitor cells,
osteoblasts, as facilitators of allogeneic stem cell engraftment.
Osteoblasts, puriﬁed from donor murine long bones, were
cotransplanted with marrow stem cells into fully allogeneic
mouse strains. The mice that received transplants demon-
strated long-term survival, were free of disease, and were
entirely engrafted with cells of both the allogeneic donor and
syngeneic donor strains. Thus, bone progenitor cells or
osteoblasts were found to represent an essential component of
the stromal cell population that can facilitate engraftment of
marrow stem cells in an allogeneic environment. In recent
experiments, El-Badri et al. [108] extended their investigations
to evaluate the capability of highly purified preparation of
HSCs from healthy donors to prevent the development of
glomerulonephritis and vasculitis in an autoimmune-prone
mouse strain. Initially, pure allogeneic HSCs failed to engraft
in the (NZW × BXSB)F1 (W/B)F1 mice that received trans-
plants whether HSCs were transplanted alone or with
osteoblasts. To promote engraftment, the investigators gradu-
ally expanded the number of allogeneic HSCs to 2-5 million
cells and with this change successfully engrafted and reconsti-
tuted the lymphohematopoietic systems of the transplant recip-
ients. Histologically, the mice that received transplants were
free of the glomerulonephritis and the vasculitis of the heart
and the lung that is characteristic of mice of this strain [108].
Future Experiments Using Mouse Models
Because Ildstad and colleagues [109] concluded that
lethal preparative measures would not be acceptable for
preparations to treat autoimmune diseases, we plan now to
use a more gentle method of producing stable mixed
chimerism, which was described by Sharabi and Sachs about
10 years ago [110] to achieve mixed marrow transplantation
and mixed hematopoietic chimerism without lethal irradia-
tion. The protocol [111] utilizes monoclonal antibodies to
the mature T-cell subsets (CD4 and CD8) to eliminate the
T cells, which otherwise resist engraftment of allogeneic
bone marrow. This treatment permits engraftment with a
very low dose of whole body irradiation of 3 Gy plus 7 Gy
local x-irradiation to the thymus or even no radiation if
very large quantities of donor bone marrow are used. Other
diseases that we are approaching using this gentle manipu-
lation will include diabetes type I in NOD mice; the ather-
osclerosis of ApoE–/– knockout mutant mice that have not
been cured by BMT or stem cell transplantation (SCT); and
the senility-accelerated disease in SAM-P mice that is
accompanied by and driven by autoimmunities.
IMMUNE TOLERANCE MECHANISMS
Immune tolerance can be defined as the enduring
acceptance of a viable organ or tissue graft from a geneti-
cally different individual without the need for permanent
immunosuppression [111,112]. Various attempts have been
made to induce persistent and complete tolerance across
MHC barriers to ultimately be applied to organ transplanta-
tion in humans. Tolerance as produced by BMT involves
3 mechanisms: clonal deletion, anergy, and cellular mecha-
nisms of immunosuppression. Associated with these pro-
posed mechanisms are a number of treatment protocols
which have been correlated with varying degrees of success-
ful tolerance induction. Clonal deletion, which occupies the
main part of self-tolerance, is induced by reconstituting
lethally irradiated recipients with donor hematolymphoid
cells [113]. We have previously reported [84,85,114] that
successful organ allografts can be achieved by carrying out
BMT in conjunction with organ allografts, thus creating
stable mixed chimerism. It has recently been noted that
potent and persistent tolerance may be induced using clonal
anergy mechanisms (absence of signals from co-stimulatory
molecules in an interaction between host T cells and anti-
gen-presenting cells) and clonal suppression mechanisms
(the term clonal suppression can reflect the concept that
immunosuppressive treatment involves alteration of nonspe-
cific regulator cells leading to death in some effector cell
populations and a lack of responsiveness in others) [115,116].
Morita et al. [117] in Ikehara’s laboratory in Osaka,
Japan, have established donor-speciﬁc tolerance across MHC
barriers to skin allografts by portal venous (PV) injection of
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allogeneic cells without using any chemical immunosuppres-
sants and/or irradiation. Recently, the mechanism by which
the donor-speciﬁc tolerance is induced after PV injection has
been found to be due to induction of clonal anergy in the
CD8+ T cells of the recipients [118]. This tolerance appears
to be maintained by suppression of the function of donor-
reactive T helper (Th)1 cells via a dominant influence of
their Th2 counterpart [116]. These investigators have previ-
ously found that even when injected intravenously (IV), bone
marrow cells accumulate mainly in the host liver but not in
the bone marrow or spleen. Zhang et al. [119] examined the
fate of the injected allogeneic spleen cells and the migration
patterns of allogeneic spleen cells, bone marrow cells, and
thymocytes after their administration via different routes.
They showed that using the PV route suppresses donor-
speciﬁc rejection, although the preimmunization of recipi-
ents with allogeneic thymocytes via the PV route induces a
rapid removal of subsequently IV injected donor spleen
cells. These findings indicated that the allogeneic HSCs
trapped in the liver may play a crucial role in the induction
and maintenance of the tolerance induced by the PV route.
Based on the above ﬁndings and using an initial PV injec-
tion of spleen cells or bone marrow cells plus IV injection of
hematopoietic bone marrow cells followed by application of
skin allografts, we presented a single-day protocol for the
induction of potent and durable immunologic tolerance
across MHC barriers that may prove more applicable to
organ transplantation in humans than would a protocol that
requires several days to complete [117].
With the establishment of a single-day protocol, Morita
et al. modiﬁed this method and applied it to pigs [120] and
guinea pig-to-mice xenogeneic transplantations [121]. Allo-
geneic bone marrow cells of donor pigs were injected using
the PV route. The pigs accepted donor allografts, autolo-
gous grafts, and third-party grafts at the same time. One
hundred percent of skin allografts were achieved, conﬁrm-
ing that this strategy can overcome MHC barriers and, even
in pigs, produce donor-speciﬁc tolerance over the allogeneic
barriers, although an immunosuppressant such as cyclo-
sporin A or tachrolimus is necessary. The combination of
PV-induced tolerance using a single-day protocol plus pilot
skin grafts could be a great advantage to organ transplanta-
tion in humans [120,121].
THE FUTURE OF XENOTRANSPLANTATION
At the entrance of a new era in which tolerance can be
produced by creating stable mixed macrochimerism and clin-
ical xenotransplantation, the transplantation of organs and
tissues between animal species is becoming a valid option,
owing primarily to the severe shortage of allogeneic donor
organs. In addition to the ability to increase the availability
of donor organs, xenotransplantation offers great advantages
over allogeneic transplantation, including the ability to
genetically engineer the donor xenograft and the resistance
of some xenografts to infection by human viruses [122].
Xenotransplantation was ﬁrst performed in the 1960s in sev-
eral patients suffering from renal failure who received kid-
neys from chimpanzee donors [123-125]. Six of 7 patients
who received the kidney transplants immediately demon-
strated physiological activity and despite treatment with
immunosuppressive agents, acute rejection occurred. Five
patients died from over-immunosuppression. One kidney
functioned normally for 6 months. Starzl et al. [126]
observed early graft function in kidneys transplanted from
baboon donors. These patients received immunosuppressive
agents and local irradiation to prevent acute rejection. How-
ever, as in the previous study, most patients died from sepsis
related to the immunosuppression. The longest surviving
patient’s kidney functioned for almost 60 days. These 2 stud-
ies showed that the most current immunosuppressive thera-
pies are unable to control acute xenogeneic rejection and
were, in fact, too toxic. The discovery of cyclosporine and
tacrolimus prompted investigators to reattempt xenotrans-
plantation. The pig is the most suitable donor animal for
humans because these animals are anatomically and physio-
logically sufﬁciently similar to humans, although xenografts
used for human transplantation are normally destroyed by
the host within minutes by hyperacute xenograft antibody
complement-based rejection, despite the use of immunosup-
pressive agents [127]. An improved understanding of the
immune recognition and rejection of xenografts has resulted
in new techniques for producing stable mixed chimerism and
xenogeneic tolerance. Considerable progress has been made
in our understanding of the molecular genetic basis of the
rapid hyper-acute antibody-mediated rejection mechanisms
that occur in xenogeneic organ rejection [128]. However, the
prompt and vigorous immune response to xenogeneic tissue
still remains a signiﬁcant barrier to clinical xenotransplanta-
tion [121]. The use of partial conditioning regimens to pro-
mote engraftment of xenogeneic HSCs, the development of
donor-speciﬁc tolerance, and solutions to the remaining hur-
dles in clinical application may eventually make xenotrans-
plantation in humans a clinical reality [122].
ALLOGENEIC VERSUS AUTOLOGOUS OR SYNGENEIC BMT
In contrast to the impressive success of alloBMT for
treatment, our preclinical results do not reveal comparable
promise for autologous or syngeneic BMT for treatment of
mice that may already have developed systemic autoimmune
disease. The findings in autoimmune-prone mice support
the ultimate application of BMT from allogeneic donors not
prone to develop systemic autoimmune diseases as an
approach to prevent or treat life-threatening autoimmune
disease [80,82,87,129-131].
Allogeneic Versus Syngeneic BMT
In genetically determined autoimmune disease in animal
models, the superiority of alloBMT over syngeneic marrow
transplantation has been repeatedly demonstrated in our
experiments. We have never carried out autologous BMT to
test its potential value for preventing or treating autoim-
mune diseases in mice. However, syngeneic BMT in these
autoimmune models has never been followed by effective
treatment or prevention of disease. By contrast, alloBMT
from autoimmune-prone mice produces genetically deter-
mined autoimmune disease after intensive irradiation, with
or without additional chemotherapy [132].
Autoimmunities of NZB, B/WF1, BXSB, MRL/lpr,
W/BF1, and NOD mice have each been caused when BMT
or stem cell transplants from these autoimmune-prone
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strains are given to strains of mice that do not ordinarily
develop or express any autoimmune disease. Such transfers
of disease by stem cells were first seen by Ikehara et al.
[133] and Sardiña et al. [134] with NZB donors. Kirzner
[135] extended these findings using stem cell preparations
to produce the characteristic autoimmunities and disease
from (NZW × BXSB)F1 (W/B)F1 hybrid donors to
B6C3F1 nonautoimmune recipients. Kirzner demonstrated
for the ﬁrst time the prevention [136] of degenerative CVD
in autoimmune-prone male W/BF1 mice by the transplan-
tation of haploidentical TCD marrow or HSC prepara-
tions. Closer examination of the progression and develop-
ment of autoimmunity in a previously nonautoimmune
strain, such as B6C3F1, may provide additional information
concerning the relationship between autoimmunity, which
arises from a genetic predisposition, and the effect of host
inﬂuences, including thymic education, induction of toler-
ance, and other yet-to-be-defined influences on the
engrafted hematopoietic and immunologic cellular systems.
Diseases Not Cured by Lethal TBI + Syngeneic or
Autologous BMT or Stem Cell Transplantations
There have recently been reports on the rapid recur-
rence or persistence of autoimmune diseases after lethal
TBI plus syngeneic or autologous BMTs or stem cell trans-
plantations in classic lupus (B/W)F1 mice; idiopathic
thrombocytopenia purpura, multiple autoimmunities, and
lethal renal disease in NZB mice; fulminating glomeru-
lonephritis, occlusive CVD, and lethal coronary occlusions
that were correlated with anticardiolipin antibodies in the
(NZW × BXSB)F1 (W/B)F1 model; Sjögrens syndrome in
MRL/+ old female mice; severe polyarthritis in NZB/Kn
male mice; and type I diabetes in the NOD mice. None of
these diseases can be prevented or cured after lethal TBI
coupled with syngeneic BMT (personal observations).
Although we have not attempted to prevent or treat organ-
specific or systemic autoimmunities by autologous BMT,
we believe the failure of syngeneic BMT to prevent or cure
these diseases is sufficient. Another observation that sup-
ports the crucial role of alloBMT as the best approach to
prevention or treatment of autoimmune disease is the
demonstration that lethally irradiated strains of mice that
do not naturally develop autoimmune diseases sponta-
neously can regularly be induced to develop autoimmune
diseases by passively transferring the autoimmune disease
in its appropriate expression by BMT from the autoim-
mune-prone mice to the autoimmunity-free mice [82,129].
Mixed Allogeneic Plus Syngeneic BMT and Stable
Mixed Chimerism
We have found that mixed allogeneic plus syngeneic
BMT offers an effective and well-tolerated—and often dra-
matic—approach to treating high-risk and often lethal
autoimmune, renal, and cardiovascular diseases in mice. The
possibility of applying these approaches to humans deserves
consideration. Further application of the gentler, kinder
methods to produce stable mixed macrochimerism seems
especially attractive as an option to achieve regular and
durable immunologic tolerance in allotransplantation and
even xenotransplantation of organs and tissues in humans, as
well as in experimental animals.
CONCLUSION
The “experiments of nature” that pointed the way to
the discovery of the role of the thymus, the germinal cen-
ters, and the plasma cells in the immune system led to the
development of a most important approach to treating dis-
ease—cellular engineering. Thus, we believe that the future
of cellular engineering continues to be bright. Fortunately,
technical hurdles such as those confronting gene therapy
today are not insurmountable. With much ingenuity and
several essential discoveries, gene therapy will follow, at
ﬁrst with halting steps, then a brisk walk, and, ultimately, a
full run, when gene therapy protocols are applied to trans-
plantation much sooner than some think.
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